Ivenix Appoints John Douglass as Board of Directors Executive Chair
Will Focus on Growth Strategy and Advancing Commercialization
North Andover, MA, February 25, 2019 – Ivenix, a medical technology company with the vision of eliminating infusion-related patient harm, today announced that John Douglass has assumed the position of executive chair of the Board of Directors. In this role, Mr. Douglass will drive the strategic vision of Ivenix with heightened focus on commercialization initiatives.
“John has over three decades of experience developing innovative healthcare technology aimed at improving patient care,” stated Ketan Patel, M.D., Ivenix board member and partner at F-Prime Capital. “His operational and commercial leadership experience will be crucial at this important time in the company’s juncture.”
Mr. Douglass has served on the Ivenix board for over eight years. Previously, he served as the president of Capsule, where he headed U.S. operations and sales along with worldwide marketing and business development. Prior to Capsule, John co-founded Sentillion, later acquired by Microsoft, a provider of identity and access management solutions.
“I’m excited to take on this more active role with such a creative and hardworking team,” said Mr. Douglass. “We’re on a mission to bring critical innovation to the industry, aiming to reduce infusion related errors, decreasing total cost of ownership and breaking new ground by continuously improving the system with regular releases of enhanced capabilities.”
Ivenix, Inc. is a medical technology company with a vision to eliminate infusion related patient harm. The company was founded to develop innovative solutions to transform infusion delivery. Ivenix designed an infusion system from the ground up to streamline medication delivery and bring legacy technology into the digital age. The Ivenix Infusion System includes a large volume infusion pump supported by a robust infusion management system designed to set new standards in usability, medication precision, and interoperability. The Ivenix Infusion System is currently under 510(k) review by the U.S. Food and Drug Administration. For more information, visit www.ivenix.com or follow @IvenixInc on Twitter.